GlassScriptPhysician profile
Shrinivas M Diggikar
NPI 1942248901
$5,838.87
in general payments reported to CMS, 2019-2025
21 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,932 · 2020: $26.63 · 2021: $23.89 · 2022: $43.83 · 2023: $76.11 · 2024: $1,475 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,310 · Food and Beverage: $446 · Travel and Lodging: $40.80 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,310.00 |
| Food and Beverage | $445.79 |
| Travel and Lodging | $40.80 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $2,455.39 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $1,458.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,407.53 | 2019-2024 | Imfinzi |
| Eisai INC. | $55.53 | 2022-2023 | |
| Array Biopharma INC | $52.05 | 2025 | Braftovi, Lorbrena, Xalkori |
| Genzyme Corporation | $47.20 | 2025 | |
| Merck Sharp & Dohme LLC | $39.00 | 2020-2023 | Keytruda |
| Kite Pharma, INC. | $38.24 | 2024-2025 | Yescarta |
| Seagen INC. | $35.90 | 2019-2022 | |
| Pharmaessentia USA Corporation | $34.83 | 2024 | Besremi |
| Regeneron Healthcare Solutions, INC. | $31.00 | 2025 | Libtayo |
| Acrotech Biopharma INC. | $23.94 | 2021-2022 | |
| Immunocore Limited | $21.79 | 2025 | Kimmtrak |
| Caris Mpi, INC. | $21.33 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $19.91 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $19.40 | 2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $18.96 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2025 | Fruzaqla |
| Blueprint Medicines Corporation | $15.80 | 2023 | Ayvakit |
| Glaxosmithkline, LLC. | $14.18 | 2024 | Ojjaara |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrinivas Diggikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.